Kawasaki Vs MIS-C

Introduction

The emergence of Multisystem Inflammatory Syndrome in Children (MIS-C) during the COVID-19 pandemic presented significant diagnostic challenges due to its phenotypic resemblance to Kawasaki Disease (KD).
Both conditions present with persistent fever, systemic hyperinflammation, and mucocutaneous manifestations.
Distinguishing these entities remains critical because management strategies and cardiac prognoses differ significantly.

Comparision

Clinical Feature	Kawasaki Disease (KD)	Multisystem Inflammatory Syndrome In Children (MIS-C)
Age Of Onset	Infants and young children under 5 years; median age approximately 2 years.	Older children and adolescents; median age 8 to 11 years.
Ethnic Predisposition	Higher incidence in East Asian descent populations.	Disproportionately affects African, Afro-Caribbean, and Hispanic ancestry.
Etiology	Unknown trigger; likely ubiquitous agent.	Post-infectious immune dysregulation following SARS-CoV-2 infection.
Fever Duration	Prolonged, classically unremitting for greater than 5 days.	Prolonged, > 38.0°C for $\geq$ 24 hours, commonly lasting 3 to 5 days.
Shock And Hypotension	Exceedingly rare, occurring in less than 5% of cases.	Defining feature, occurring in 50–80% of cases requiring vasopressor support.
Gastrointestinal Signs	Mild vomiting or diarrhea; less common.	Prominent in 80-90% of cases; severe abdominal pain mimicking appendicitis.
Cardiac Pathology	Primary complication is coronary artery vasculitis causing destructive aneurysms.	Primary complication is acute myocarditis triggering cytokine-induced dysfunction.
Ventricular Function	Left ventricular systolic function typically remains preserved.	Moderate to severe left ventricular dysfunction commonly occurs.
Platelet Count	Characterized by marked thrombocytosis in the subacute phase.	Characterized by profound thrombocytopenia (<150,000/μL).
Lymphocyte Count	Normal or features mild decrease.	Profound absolute lymphopenia.
Specific Biomarkers	Mild D-Dimer elevation; moderately elevated Ferritin.	Massively elevated D-Dimer indicating coagulopathy; Ferritin >500–1000 ng/mL.
Cardiac Biomarkers	Troponin and BNP exhibit mild elevation.	Troponin and BNP/NT-proBNP demonstrate massive elevation.
Viral Serology	Typically negative for SARS-CoV-2 antibodies unless coincidental.	Universal positive IgG/IgM serology indicating past SARS-CoV-2 infection.
Standard Therapy	Intravenous Immunoglobulin (2 g/kg) combined with Aspirin.	Intravenous Immunoglobulin (2 g/kg) combined with Corticosteroids and low-dose Aspirin.

Epidemiological And Clinical Divergence

KD exhibits a well-documented predilection for young children of East Asian descent, suggesting underlying genetic susceptibility.
MIS-C predominantly strikes school-aged children and teenagers, an age demographic where classic KD remains historically rare.
While mucocutaneous manifestations such as conjunctivitis, strawberry tongue, and extremity edema define KD, they frequently manifest incompletely or transiently in MIS-C.

Cardiovascular Pathophysiology

KD drives direct coronary artery vasculitis, threatening the patient with long-term arterial stenosis and thrombosis if aneurysms develop.
MIS-C primarily triggers acute myocarditis resulting in significant, albeit typically transient, left ventricular dysfunction.
Coronary artery dilation observed during MIS-C results primarily from vasodilation induced by the hyperinflammatory state, rendering giant aneurysms rare.

Laboratory Profile Divergence

The complete blood count delivers the most reliable differentiating signature, termed the platelet paradox.
KD universally associates with thrombocytosis during disease progression, while MIS-C features consumption coagulopathy leading to thrombocytopenia.
MIS-C features a laboratory profile closely resembling Macrophage Activation Syndrome, characterized by profound lymphopenia, neutrophilia, and extreme Ferritin elevations.

Management Protocols

Standard KD therapy relies strictly on Intravenous Immunoglobulin combined with Aspirin.
MIS-C mandates aggressive upfront dual immunomodulation utilizing Intravenous Immunoglobulin and Corticosteroids like Methylprednisolone, alongside low-dose Aspirin.
Severe MIS-C cases demonstrating refractory shock or high thrombosis risk uniquely require adjunctive anticoagulation utilizing Enoxaparin and targeted biological agents like Anakinra or Tocilizumab.